MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Myomo Accounts Receivables 2011-2025 | MYO
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Myomo
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.9 M | 1.96 M | 925 K | 424 K | 382 K | 297 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.96 M | 297 K | 981 K |
Quarterly Accounts Receivables Myomo
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.29 M | 7.05 M | 4.66 M | 3.83 M | 3.73 M | 2.53 M | 1.68 M | 2.38 M | 2.52 M | 1.64 M | 1.55 M | 1.9 M | 1.6 M | - | 1.69 M | 1.96 M | 2.22 M | 1.13 M | 765 K | 925 K | 925 K | 925 K | 925 K | 424 K | 424 K | 424 K | 424 K | 382 K | 382 K | 382 K | 382 K | 297 K | 297 K | 297 K | 297 K | 115 K | 115 K | 115 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.05 M | 115 K | 1.53 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
97.2 M | - | - | $ 17.2 B |  USA |
 |
Acutus Medical
AFIB
|
11.4 M | - | -26.83 % | $ 2.62 M | USA |
 |
Apyx Medical Corporation
APYX
|
14 M | $ 3.82 | -1.04 % | $ 132 M | USA |
 |
Bio-Rad Laboratories
BIO
|
452 M | $ 307.08 | -0.33 % | $ 8.66 B | USA |
 |
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | USA |
 |
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | USA |
 |
Bruker Corporation
BRKR
|
566 M | $ 45.69 | 1.24 % | $ 6.81 K | USA |
 |
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | USA |
 |
Abbott Laboratories
ABT
|
6.92 B | $ 128.67 | 2.55 % | $ 224 B | USA |
 |
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | USA |
 |
EDAP TMS S.A.
EDAP
|
18.6 M | $ 3.18 | 10.56 % | $ 119 M |  France |
 |
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
43.1 M | - | -10.19 % | $ 1.99 M | USA |
 |
Eargo
EAR
|
1.91 M | - | - | $ 10.2 M | USA |
 |
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | USA |
 |
Cognyte Software Ltd.
CGNT
|
175 M | $ 9.58 | -2.84 % | $ 688 M |  Israel |
 |
InMode Ltd.
INMD
|
10.5 M | $ 14.35 | -1.1 % | $ 1.14 B | Israel |
 |
IRIDEX Corporation
IRIX
|
6.73 M | $ 0.99 | 7.52 % | $ 16 M | USA |
 |
IRadimed Corporation
IRMD
|
10.6 M | $ 96.99 | 0.79 % | $ 1.23 B | USA |
 |
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
996 M | $ 163.04 | -1.44 % | $ 12.2 B | USA |
 |
Accuray Incorporated
ARAY
|
83.2 M | $ 1.04 | -2.06 % | $ 107 M | USA |
 |
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
4.71 M | $ 12.5 | -1.66 % | $ 338 M | USA |
 |
AxoGen
AXGN
|
24.1 M | $ 30.0 | -1.3 % | $ 1.33 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
595 K | - | -0.57 % | $ 7.12 M | USA |
 |
CONMED Corporation
CNMD
|
238 M | $ 40.3 | -1.29 % | $ 1.24 B | USA |
 |
LivaNova PLC
LIVN
|
193 M | $ 63.28 | 0.84 % | $ 3.43 B |  Britain |
 |
OrthoPediatrics Corp.
KIDS
|
42.4 M | $ 17.83 | 1.31 % | $ 411 M | USA |
 |
Globus Medical
GMED
|
558 M | $ 86.73 | 0.05 % | $ 11.8 B | USA |
|
LENSAR
LNSR
|
6.08 M | $ 11.51 | -0.04 % | $ 133 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
272 M | $ 13.51 | 0.67 % | $ 1.04 B | USA |
 |
Aziyo Biologics
AZYO
|
3.26 M | - | 1.37 % | $ 20.5 M | USA |
 |
Alphatec Holdings
ATEC
|
83 M | $ 19.79 | -0.85 % | $ 2.83 B | USA |
 |
Aethlon Medical
AEMD
|
128 K | $ 3.07 | -9.71 % | $ 4.79 M | USA |
 |
Establishment Labs Holdings
ESTA
|
65 M | $ 72.39 | -0.17 % | $ 2.04 B |  Costa-rica |